Merck started its Acceleron pursuit at $160 per share, but CEO Davis balked at paying more than $180news2021-10-12T15:23:38+00:00October 12th, 2021|Fierce Pharma|
Spinoff or $54B sale? GlaxoSmithKline’s consumer health outfit draws buyout interest: reportnews2021-10-12T14:47:41+00:00October 12th, 2021|Fierce Pharma|
Viatris to close former Novartis site in California in January, lay off 75news2021-10-12T13:21:42+00:00October 12th, 2021|Fierce Pharma|
Merck’s oral COVID-19 drug sees India’s Everest Organics hit start on productionnews2021-10-12T12:34:53+00:00October 12th, 2021|Fierce Pharma|
Eyes itching from allergies? Ocular’s Dextenza wins FDA approval as first monthly implantnews2021-10-12T09:51:50+00:00October 12th, 2021|Fierce Pharma|
Supernus strikes $400M+ Adamas buyout as its top drug heads toward the patent cliffnews2021-10-11T19:06:51+00:00October 11th, 2021|Fierce Pharma|
Pacira boosts nonopioid pain portfolio via $450M Flexion buy, with more CVR payments to comenews2021-10-11T15:27:49+00:00October 11th, 2021|Fierce Pharma|
Pacira boosts non-opioid pain portfolio via $450M Flexion buy, with more CVR payments to comenews2021-10-11T15:27:49+00:00October 11th, 2021|Fierce Pharma|
Ipsen poaches Novartis vet Mari Scheiffele to serve as president of its international specialty care teamnews2021-10-11T15:06:01+00:00October 11th, 2021|Fierce Pharma|
Ipsen poaches Novartis vet Scheiffele to serve as president of its international specialty care teamnews2021-10-11T15:06:01+00:00October 11th, 2021|Fierce Pharma|
